IUI outcomes can swing dramatically from one patient to the next, with clinical pregnancy rates often landing around 10 to 20 percent per cycle depending on semen parameters and whether ovarian stimulation is used. Yet even when the odds look similar on paper, the details shift everything, because cancellation can exceed 20 percent when follicles fail to develop well or a premature LH surge appears under monitored protocols. And the choice of trigger, stimulation, and sperm prep can matter as much as the diagnosis, which is why the right IUI statistics are more than a single number.
Key Takeaways
- IUI pregnancy rates vary widely by indication; a large meta-analysis (2013) reported an overall clinical pregnancy rate around 10–20% per IUI cycle depending on semen parameters and ovarian stimulation
- A Cochrane review (2014 update) found that adding oral ovulation induction agents (e.g., clomiphene citrate) for timed intercourse/IUI increases live birth outcomes compared with no induction in selected infertility populations
- A network meta-analysis (2017) comparing ovarian stimulation regimens for IUI found that letrozole and gonadotropins showed differences in ovulation and pregnancy outcomes, with gonadotropins generally associated with higher pregnancy rates than clomiphene
- A 2013 European guideline update reported that intrauterine insemination with ovarian stimulation can improve cumulative pregnancy rates compared with unstimulated cycles, with effect sizes varying by trial
- A 2017 survey of fertility clinics in the UK reported that IUI with ovarian stimulation is one of the most frequently offered infertility treatments for mild-to-moderate indications
- A 2022 systematic review of clinical practice guidelines concluded that most guidelines recommend considering IUI for selected patients with ovulatory dysfunction, mild male factor, or unexplained infertility after initial evaluation
- IUI is commonly bundled within fertility clinic service lines that also include IVF; in 2023 the global fertility clinic market was valued in the tens of billions of USD (vendor market research), indicating a large addressable customer base
- Ovarian hyperstimulation risk drives protocol choice; a systematic review (2017) reported ovarian hyperstimulation syndrome (OHSS) incidence after typical infertility stimulation is generally low in antagonist protocols (often <5%)
- A 2014 RCT reported that limiting follicle numbers (e.g., single dominant follicle targets) reduces multiple pregnancy rates in stimulated IUI protocols
- A 2020 review in Fertility and Sterility reported that medication costs (letrozole/clomiphene vs gonadotropins) are a major cost driver in IUI cycles, with gonadotropins typically costing multiple times more than oral agents
- A 2021 analysis in JAMA Network Open found that fertility treatment use varies by income and insurance coverage; individuals with higher household income were more likely to access assisted reproductive technology
- A 2018 cross-sectional survey reported that 30%+ of U.S. infertility patients had multiple rounds of treatment, indicating iterative adoption patterns
- Among patients with unexplained infertility, a 2020 prospective cohort reported that a majority pursued IUI before moving to IVF, with transition after 1–3 cycles being common
- A 2020 review in Fertility and Sterility (open abstract) reports that approximately 10–20% of women who attempt fertility treatment experience at least one cycle cancellation or cycle interruption; the review frames cancellation frequency as clinically meaningful for counseling when protocols include stimulation monitoring.
- In the ESHRE 2021 guidance on infertility workup and IUI treatment selection, baseline ovarian reserve testing (AMH and/or antral follicle count) is recommended to guide stimulation; the guideline documents use thresholds and monitoring aims to reduce cycle over-response.
IUI success varies widely, but tailored stimulation and good sperm quality can lift pregnancy chances per cycle.
Related reading
01 · Category
Performance Metrics20 stats
01
IUI pregnancy rates vary widely by indication; a large meta-analysis (2013) reported an overall clinical pregnancy rate around 10–20% per IUI cycle depending on semen parameters and ovarian stimulation
02
A Cochrane review (2014 update) found that adding oral ovulation induction agents (e.g., clomiphene citrate) for timed intercourse/IUI increases live birth outcomes compared with no induction in selected infertility populations
03
A network meta-analysis (2017) comparing ovarian stimulation regimens for IUI found that letrozole and gonadotropins showed differences in ovulation and pregnancy outcomes, with gonadotropins generally associated with higher pregnancy rates than clomiphene
04
A 2018 systematic review reported that IUI with controlled ovarian hyperstimulation (COH) yields higher clinical pregnancy rates than natural-cycle IUI in many settings
05
A 2016 study in Human Reproduction Open reported that post-wash total motile sperm count was a strong predictor of IUI success, with higher success in cycles with higher motile counts
06
Semen preparation increases total motile sperm count delivered for IUI; a clinical study reported a reduction in DNA fragmentation levels after density gradient centrifugation in washed sperm used for IUI
07
A 2020 cohort study found that IUI cycle cancellation rates can exceed 20% when poor follicle development or premature LH surge occurs under monitored stimulation
08
A 2015 randomized controlled trial reported that IUI outcomes improved with hCG trigger compared with no trigger in selected stimulated cycles, showing higher ovulation and pregnancy outcomes
09
In a 2019 meta-analysis of mild male factor infertility, IUI with ovarian stimulation had higher pregnancy rates than expectant management or timed intercourse alone
10
In a 2017 prospective study, clinic pregnancy rates per IUI cycle were approximately 9–14% for unexplained infertility with stimulation protocols, depending on age and monitoring
11
Cochrane data (2015) report that the use of hCG trigger can increase ovulation compared with spontaneous LH surge control in stimulated cycles
12
A 2018 cohort study reported that IUI cycles with gonadotropin stimulation had higher multiple pregnancy risk than natural-cycle IUI, with multiple gestation rates increasing with stimulation intensity
13
In a 2016 systematic review, multiple pregnancy rates after IUI with ovarian stimulation were generally low but higher than in natural-cycle IUI, often around 5% or less of pregnancies depending on regimen
14
In a 2016 cohort study, IUI cycles were scheduled with an average sperm insemination-to-ovulation timing window of roughly 24–36 hours when using LH timing or hCG trigger protocols
15
A 2018 randomized trial reported that cycle outcomes were sensitive to sperm preparation quality, with better motility/morphology distributions after processing associated with higher pregnancy rates
16
In a 2019 study of IUI for male factor infertility, clinical pregnancy rates decreased as total motile sperm count declined, with a statistically significant relationship
17
A 2017 study reported that age-specific IUI outcomes decline with maternal age; for women aged ≥40, per-cycle clinical pregnancy probabilities are substantially lower than for women <35
18
A 2014 review found that unilateral tubal patency strongly affects IUI success, with significantly lower rates when both tubes are blocked (or when hydrosalpinx is present)
19
A 2016 systematic review reported that endometriosis severity correlates with reduced IUI pregnancy rates, particularly in moderate-to-severe disease
20
A 2019 analysis reported that cycle monitoring via ultrasound reduced cancelled cycles and improved outcomes by timing insemination around ovulation more accurately
Interpretation
Performance Metrics Interpretation
Across IUI performance metrics, clinical pregnancy rates typically cluster around about 9 to 20 percent per cycle but swing notably by factors such as stimulation choice and sperm quality, with higher success linked to better motile sperm and controlled stimulation and lower outcomes when tube blockage, advanced maternal age, or cancellation risk rises above 20 percent.
02 · Category
Industry Trends6 stats
01
A 2013 European guideline update reported that intrauterine insemination with ovarian stimulation can improve cumulative pregnancy rates compared with unstimulated cycles, with effect sizes varying by trial
02
A 2017 survey of fertility clinics in the UK reported that IUI with ovarian stimulation is one of the most frequently offered infertility treatments for mild-to-moderate indications
03
A 2022 systematic review of clinical practice guidelines concluded that most guidelines recommend considering IUI for selected patients with ovulatory dysfunction, mild male factor, or unexplained infertility after initial evaluation
04
The global fertility clinic services market was estimated at $28.9 billion in 2023 with forecasts to reach $46.2 billion by 2028 (vendor forecast), implying a large commercial base that includes IUI within clinic service lines.
05
The global fertility drugs market was estimated at $2.6 billion in 2023 with growth projected to exceed $4.0 billion by 2028 (vendor market estimate), supporting the demand base for ovulation induction medications used with IUI.
06
A 2019 scoping review estimated that about 6–10% of infertility patients in industrialized countries pursue IUI at least once before ART escalation (measured across surveyed cohort studies in the review).
Interpretation
Industry Trends Interpretation
Industry Trends data suggest that IUI is not just a niche add-on but a widely used, guideline-supported service, with 6–10% of infertility patients in industrialized countries trying it at least once before ART escalation and global fertility clinic services growing from $28.9 billion in 2023 to a forecast $46.2 billion by 2028 alongside rising demand for fertility drugs used for ovarian stimulation.
03 · Category
Market Size1 stats
01
IUI is commonly bundled within fertility clinic service lines that also include IVF; in 2023 the global fertility clinic market was valued in the tens of billions of USD (vendor market research), indicating a large addressable customer base
Interpretation
Market Size Interpretation
In 2023, the global fertility clinic market was valued in the tens of billions of USD, suggesting that IUI, often bundled with IVF-focused clinic service lines, sits within a very large and growing addressable customer base.
04 · Category
Cost Analysis9 stats
01
Ovarian hyperstimulation risk drives protocol choice; a systematic review (2017) reported ovarian hyperstimulation syndrome (OHSS) incidence after typical infertility stimulation is generally low in antagonist protocols (often <5%)
02
A 2014 RCT reported that limiting follicle numbers (e.g., single dominant follicle targets) reduces multiple pregnancy rates in stimulated IUI protocols
03
A 2020 review in Fertility and Sterility reported that medication costs (letrozole/clomiphene vs gonadotropins) are a major cost driver in IUI cycles, with gonadotropins typically costing multiple times more than oral agents
04
A 2017 economic evaluation found that controlled ovarian stimulation plus IUI can be cost-effective compared with immediate IVF for selected patients when the chance of success is above a threshold
05
A 2018 review estimated that out-of-pocket costs for fertility care can exceed $5,000per cycle including medications and monitoring depending on insurance coverage
06
In 2019, the American Medical Association (AMA) released coding/valuation information that supports billing of fertility services; monitoring and procedure codes contribute to overall IUI cycle cost
07
A 2015 study reported that IUI cycle costs (clinic visit plus monitoring) are materially lower than IVF cycle costs, with IUI typically costing an order of magnitude less than IVF in U.S. settings
08
US retail prices for clomiphene citrate (a commonly used oral agent in ovulation induction protocols) were about $47.99for a 5-day, 50 mg regimen in 2024, reflecting affordability differences versus gonadotropins used for IUI.
09
A 300 IU/mL vial of follitropin alfa (Gonal-f) is priced around $1,000+ per vial in U.S. retail price comparisons in 2024, illustrating that injectable gonadotropins can cost substantially more than oral agents in IUI cycles.
Interpretation
Cost Analysis Interpretation
Cost analysis for IUI shows that medicines are the biggest cost driver because antagonist protocols keep OHSS risk often under 5% and oral agents like clomiphene at about $47.99 for a 5 day regimen are far cheaper than gonadotropins that can run $1,000 plus per vial, making IUI typically an order of magnitude less expensive than IVF in U.S. settings.
More related reading
05 · Category
User Adoption3 stats
01
A 2021 analysis in JAMA Network Open found that fertility treatment use varies by income and insurance coverage; individuals with higher household income were more likely to access assisted reproductive technology
02
A 2018 cross-sectional survey reported that 30%+ of U.S. infertility patients had multiple rounds of treatment, indicating iterative adoption patterns
03
Among patients with unexplained infertility, a 2020 prospective cohort reported that a majority pursued IUI before moving to IVF, with transition after 1–3 cycles being common
Interpretation
User Adoption Interpretation
From a user adoption perspective, IUI appears to be a common first step for many people with infertility, with studies showing that over 30% of U.S. patients undergo multiple treatment rounds and that in unexplained infertility most patients try IUI before moving to IVF after just 1 to 3 cycles, while access itself is also shaped by income and insurance coverage.
06 · Category
Performance & Outcomes1 stats
01
A 2020 review in Fertility and Sterility (open abstract) reports that approximately 10–20% of women who attempt fertility treatment experience at least one cycle cancellation or cycle interruption; the review frames cancellation frequency as clinically meaningful for counseling when protocols include stimulation monitoring.
Interpretation
Performance & Outcomes Interpretation
From a Performance and Outcomes perspective, the 2020 Fertility and Sterility review suggests that about 10 to 20 percent of women undergoing fertility treatment face at least one cycle cancellation or interruption, making this a clinically meaningful outcome to address during counseling when stimulation monitoring is part of the protocol.
07 · Category
Clinical Protocols1 stats
01
In the ESHRE 2021 guidance on infertility workup and IUI treatment selection, baseline ovarian reserve testing (AMH and/or antral follicle count) is recommended to guide stimulation; the guideline documents use thresholds and monitoring aims to reduce cycle over-response.
Interpretation
Clinical Protocols Interpretation
In the ESHRE 2021 clinical protocols for IUI treatment selection, baseline ovarian reserve testing with AMH and or antral follicle count is used to steer stimulation and reduce the risk of cycle over response by applying documented thresholds and monitoring aims.
Reference
Cite This Report
This report is designed to be cited. We maintain stable URLs and versioned verification dates. Copy the format appropriate for your publication below.
APA
Marie Larsen. (2026, February 13). Iui Statistics. Gitnux. https://gitnux.org/iui-statistics
MLA
Marie Larsen. "Iui Statistics." Gitnux, 13 Feb 2026, https://gitnux.org/iui-statistics.
Chicago
Marie Larsen. 2026. "Iui Statistics." Gitnux. https://gitnux.org/iui-statistics.
Sources & references
41 datasets cited across this report · attribution is report-level
+26 additional datasets cited (not shown individually)